Please ensure Javascript is enabled for purposes of website accessibility

Oceanside, California USA, June 1 – AOTI Inc. announced today that it has been Awarded a 5 Year Worldwide Federal Supply Schedule Contract (contract number: V797P-4209b) for its unique Topical Wound Oxygen Therapy (TWO2) product line.

“The Veterans Health Administration is the largest Integrated Health Network in the USA, that serves our 23 million Veteran population, operates 1,400 care sites including 154 hospitals, and treats over 9 million veterans each year. Other federal agencies, such as the Department of Defense, Bureau of Indian Affairs, and Bureau of Prisons are also covered by this contract. The award of a 5 Year Worldwide Federal Supply Schedule Contract allows us to continue to service this needy population” says Dr. Mike Griffiths, CEO and President of AOTI.
Additionally, Topical Oxygen is also reimbursed by New York State Medicaid as well as numerous other insurers nationwide. “We are pleased that healthcare professionals now recognize the real costs associated with the management of diabetic, venous, arterial and pressure ulcers and that adding Topical Wound Oxygen (TWO2) therapy to existing wound care best practices will not only reduce the total cost of care, but more importantly improve the patients quality of life”, added Griffiths.

About AOTI

AOTI is founded on a decade of experience in providing innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is unsurpassed in fully closings Diabetic, Venous and Pressure ulcers alike. AOTI is a private company based in Oceanside, California USA and Galway, Ireland with offices throughout the globe. For more information, see

Need more information?

A dedicated customer service team is here to help.